Market Size of Europe Biopsy Devices Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Market Size (2024) | USD 599.20 Million |
Market Size (2029) | USD 733.23 Million |
CAGR (2024 - 2029) | 4.12 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Biopsy Devices Market Analysis
The Europe Biopsy Devices Market size is estimated at USD 599.20 million in 2024, and is expected to reach USD 733.23 million by 2029, growing at a CAGR of 4.12% during the forecast period (2024-2029).
During the COVID-19 pandemic, the biopsy device market was significantly impacted due to the decrease in the number of biopsy procedures as a result of the COVID-19 pandemic's restrictions. As per the study published in 2021 titled "Impact of the COVID-19 Pandemic on Surgical Oncology in Europe: Results of a European Survey", of all the hospital departments, 88.4% reported a lower volume of patients in the outpatient clinic; 69.1% and 75.0% reported a reduction in the hospital bed and the operating room capacity, respectively. As a result, the participants reported an average reduction of 29.3% for all types of oncological resections. Thus, the reduction in the number of surgical procedures during the COVID-19 pandemic negatively impacted the market's growth. However, during the post-pandemic period, the postponed surgeries resumed, which boosted the market's growth.
The major factors driving the growth of the market in the Europe region include increasing preference for minimally invasive procedures, an increase in the number of cancer cases, and initiatives undertaken by the government for early diagnosis of cancer. Biopsy has been one of the major diagnosis techniques for cancer disorders and is widely used in the diagnosis of breast, skin, and prostate cancer. As per the Globocan estimates of 2020, there were about 4.40 million new cancer cases in Europe in 2020 which is expected to increase and reach up to 5.32 million by 2040. Thus, the high cases of cancer are expected to increase the demand for biopsy devices which is expected to boost the growth of Europe biopsy devices over the forecast period.
There is also a demand for minimally invasive biopsy procedures that is rising at a significant rate in the market. The different types of technologies and products, such as biopsy guiding systems, needle-based biopsy guns, and vacuum-assisted devices are anticipated to witness high growth during the forecast period. In addition, the growing awareness regarding breast cancer treatment and diagnosis will support the increase in the biopsy devices market size in the upcoming years. Many countries hold programs for the early diagnosis of breast cancer. For instance, European Week Against Cancer (EWAC) takes place between 25 and 31 May each year and is concluded by World No Tobacco Day on 31 May. During EWAC cancer charities, European policy-makers and the general public engage in various activities connected to raising awareness about cancer prevention, access to treatment, and support for patients and cancer survivors. Therefore, such initiatives are expected to accelerate the adoption rate of biopsy devices, thereby positively impacting the growth of the biopsy devices business in the foreseeable future.
Thus, owing to the above-mentioned factors the market is expected to show significant growth over the forecast period. However, product recall and availability of alternative techniques is expceted to hinder the growth of the market over the forecast period.
Europe Biopsy Devices Industry Segmentation
As per the scope of the report, the biopsy is a process that helps in the removal of tissue from an organ to determine the presence or extent of a disease, mostly cancerous and inflammatory conditions. This diagnostic procedure is generally performed by surgeons, radiologists, and interventional cardiologists, to confirm the presence of cancerous tissues. Therefore, biopsy procedures can be performed for almost any organ with the help of a specific biopsy device. The Europe Biopsy Devices Market is segmented by Product (Needle-based Biopsy Instruments, Procedure Trays, Localization Wires, and Other Products), Application (Breast Biopsy, Lung Biopsy, Colorectal Biopsy, Prostate Biopsy, and Other Applications), and Geography (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe). The report offers the value (in USD million) for the above segments.
By Product | |||||
| |||||
Procedure Trays | |||||
Localization Wires | |||||
Other Products |
By Application | |
Breast Biopsy | |
Lung Biopsy | |
Colorectal Biopsy | |
Prostate Biopsy | |
Other Applications |
Geography | |
Germany | |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe |
Europe Biopsy Devices Market Size Summary
The Europe biopsy devices market is poised for significant growth over the forecast period, driven by an increasing preference for minimally invasive procedures and a rising incidence of cancer cases. The market experienced a downturn during the COVID-19 pandemic due to restrictions that led to a decrease in biopsy procedures. However, the resumption of postponed surgeries in the post-pandemic period has bolstered market growth. Key factors contributing to the market's expansion include government initiatives for early cancer diagnosis and the widespread use of biopsy techniques in diagnosing breast, skin, and prostate cancers. The demand for minimally invasive biopsy procedures is on the rise, with technologies such as biopsy guiding systems, needle-based biopsy guns, and vacuum-assisted devices expected to witness substantial growth.
The United Kingdom stands out as a leading revenue contributor to the market, supported by its sophisticated healthcare infrastructure and the growing prevalence of cancer. The increasing number of cancer cases, particularly breast cancer, is expected to drive the demand for needle-based biopsy instruments. The market is characterized by fragmentation and competitiveness, with major players like Hologic, Becton, Dickinson and Company, and Boston Scientific Corporation actively engaging in product launches and technological innovations. Initiatives such as the introduction of liquid biopsy tests by the National Health Service in the UK and the launch of genomic profiling assays in Europe are anticipated to further propel market growth. Despite challenges like product recalls and the availability of alternative techniques, the market is expected to continue its upward trajectory, supported by ongoing advancements and strategic partnerships among key industry players.
Europe Biopsy Devices Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Preference for Minimally Invasive Procedures
-
1.2.2 Increase in the Number of Cancer Cases
-
-
1.3 Market Restraints
-
1.3.1 Product Recalls
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Product
-
2.1.1 Needle-based Biopsy Instruments
-
2.1.1.1 Core Biopsy Devices
-
2.1.1.2 Aspiration Biopsy Needles
-
2.1.1.3 Vacuum-assisted Biopsy Devices
-
-
2.1.2 Procedure Trays
-
2.1.3 Localization Wires
-
2.1.4 Other Products
-
-
2.2 By Application
-
2.2.1 Breast Biopsy
-
2.2.2 Lung Biopsy
-
2.2.3 Colorectal Biopsy
-
2.2.4 Prostate Biopsy
-
2.2.5 Other Applications
-
-
2.3 Geography
-
2.3.1 Germany
-
2.3.2 United Kingdom
-
2.3.3 France
-
2.3.4 Italy
-
2.3.5 Spain
-
2.3.6 Rest of Europe
-
-
Europe Biopsy Devices Market Size FAQs
How big is the Europe Biopsy Devices Market?
The Europe Biopsy Devices Market size is expected to reach USD 599.20 million in 2024 and grow at a CAGR of 4.12% to reach USD 733.23 million by 2029.
What is the current Europe Biopsy Devices Market size?
In 2024, the Europe Biopsy Devices Market size is expected to reach USD 599.20 million.